Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-27

Study Completion Date

2024-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of the study is to evaluate the anti-tumor activity of autologous natural killer cells in cultures of cancer cells obtained from patient's own tumor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

NCT00918658

Leukemia Multiple Myeloma and Plasma Cell Neoplasm

TERMINATED

Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia

NCT01520246

Leukemia Lymphoma

COMPLETED

Study of Specimens From Young Patients With Neuroblastoma

NCT00958659

Localized Resectable Neuroblastoma Localized Unresectable Neuroblastoma Regional Neuroblastoma +1 more

COMPLETED

Memory Phenotype and PD-1 Inhibition Response in Oral Cancer

NCT03862066

Squamous Cell Carcinoma of the Head and Neck

TERMINATED

Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma

NCT04509804

Lymphoid Neoplasm

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of the study is to evaluate the anti-tumor activity of autologous natural killer cells in cultures of cancer cells obtained from patient's own tumor.

Study Design:

One hundred mL of blood will be collected in an EDTA container and transported to the laboratory for in vitro isolation and expansion of NK cell cultures.

Two or three weeks later, 25 cu mm of the patient's own tumor will be collected in PBS and transported to the laboratory for co-culture with autologous expanded and enhanced NK cells.

Inclusion Criteria:

Individuals must meet all of the inclusion criteria in order to be eligible to participate in the study, as follows:

* Male or Female ≥ 18 years of age
* Pathologically confirmed diagnosis of locally advanced unresectable or metastatic soft tissue sarcoma
* Patients who are already scheduled for surgery
* Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the investigator's IRB/Ethics Committee
* Willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria: Patients who do not meet the inclusion criteria.

Methodology:

Male and female subjects \> 18 years of age, of any ethnicity, with advanced soft tissue sarcoma will be recruited via patient referrals from the medical community, patient request for participation through internet research, patients being treated at the Sarcoma Oncology Research.

Study Duration:

The study is expected to take 24-30 months

Statistical Analysis Plan For the in vitro studies, multiple group comparisons at a single time point will be made via the independent analysis of variance (ANOVA) test, followed by Tukey's HSD test as a post-hoc test where appropriate. Assuming the required statistical power of 0.9 with a significance level of 0.05 and effect size of 0.4, an equal sample size of at least 19 is suggested for each group: 1) Untreated, 2) CH-SCP, 3) Nk cells and 4) CH-SCP-NK-based hydrogel. Differences in mean tumor growth and survival rate between the control and experimental groups at each time point will be tested with independent ANOVA followed by Tukey's HSD test as a post-hoc analysis where appropriate.

Baseline Descriptive Statistics Demographics, age, ethnicity, subtypes of sarcoma, number of patients, patients with locally advanced or metastatic will be described using descriptive statistics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female ≥ 18 years of age
* Pathologically confirmed diagnosis of locally advanced unresectable or metastatic soft tissue sarcoma
* Patients who are already scheduled for surgery
* Ability to understand the purposes and risks of the study and has signed and dated a written informed consent form approved by the investigator's IRB/Ethics Committee
* Willingness to comply with all study procedures and availability for the duration of the study.

\-

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No